1. "CTCR Scholars"
Formats
  1. Meeting Abstract (846)
  2. Journal Article (546)
  3. Review (68)
  4. Research Letter (35)
  5. Editorial (29)
  6. Correspondence (24)
  7. Miscellaneous (16)
  8. Book Section (10)
  9. Guidelines (7)
  10. Conference Paper (4)
Groups
  1. CTCR Scholars (1585)
  2. Department of Medicine (1369)
  3. Hematologic Malignancies, Division of (1045)
  4. MSK Grad Students (989)
  5. Master of Science in Clinical and Translational Cancer Research (956)
  6. Center for Hematologic Malignancies (955)

More Groups

People
  1. Sergio Giralt (539)
  2. Miguel-Angel Perales (397)
  3. Michael Scordo (366)
  4. Gunjan Shah (321)
  5. Sean Devlin (321)
  6. Parastoo Dahi (294)

More People

Years
  1. 2025 (68)
  2. 2024 (227)
  3. 2023 (261)
  4. 2022 (230)
  5. 2021 (166)
  6. 2020 (211)

More Years

Publications
  1. Blood (294)
  2. Biology of Blood and Marrow Transplantation (187)
  3. Journal of Clinical Oncology (140)
  4. Annals of Surgical Oncology (81)
  5. Bone Marrow Transplantation (65)
  6. Transplantation and Cellular Therapy (55)

More Publications

Publishers
  1. Elsevier Inc. (390)
  2. American Society of Hematology (345)
  3. American Society of Clinical Oncology (153)
  4. Nature Publishing Group (130)
  5. Springer (98)
  6. American Association for Cancer Research (65)

More Publishers

Results (1585)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • DNA liquid biopsies for cancer-associated venous thromboembolism prediction
    Meeting Abstract

    Jee, J.; Brannon, A. R.; Fong, C.; Lee, A.; Gray, L.; Pichotta, K.; Luthra, A.; Diosdado, M.; Haque, M.; Guo, J.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Carfilzomib,lenalidomide and dexamethasone (KRd) as induction therapy in high-risk newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C.; Korde, N.; Derkach, A.; Hultcrantz, M.; Maclachlan, K. H.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; Patel, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Topical ruxolitinib for chronic cutaneous GvHD: Promising results of a phase 2 clinical trial
    Meeting Abstract

    Markova, A.; Papadopoulos, E. B.; Dusza, S.; Ostojić, J.; Ai, R.; Maier, T.; Lacouture, M.; Tamari, R.; Gyurkocza, B.; Shaffer, B. C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Patterns of cytokine release syndrome with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy
    Meeting Abstract

    Hamadeh, I. S.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • High progression-free survival with low relapse rates after double-unit cord blood transplantation in patients with high-risk AML
    Meeting Abstract

    Politikos, I.; Fingrut, W. B.; Brown, S.; Chinapen, S.; Quach, S.; Dahi, P. B.; Gyurkocza, B.; Jakubowski, A. A.; Papadopoulos, E. B.; Ponce, D. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Stem cell utilization in the era of novel therapies for multiple myeloma
    Meeting Abstract

    Nishimura, N.; Nemirovsky, D.; Devlin, S. M.; Dahi, P. B.; Landau, H.; Lahoud, O. B.; Scordo, M.; Shah, G. L.; Mailankody, S.; Hassoun, H.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Evaluating the effect of evolving changes in serum biomarkers on the risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Nemirovsky, D.; Maclachlan, K. H.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U. A.; Tan, C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • TNC/Kg and CD34+/Kg cell dose impact on patient engraftment after allogeneic transplant with conventional bone marrow; Better predictability of graft content needed
    Meeting Abstract

    Davis, E.; Feuer, E.; Rapoport, C.; Lobaugh, S.; Devlin, S. M.; Archer, A.; Chinapen, S.; Federman, J.; Kelly, A.; Klein, E.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A phase II trial of prophylactic anakinra to prevent neurotoxicity in patients receiving anti-CD19 CAR T-cell therapy for relapsed or refractory lymphoma: Final results from cohort 2
    Meeting Abstract

    Nath, K.; Devlin, S. M.; Sauter, C. S.; Palomba, M. L.; Shah, G. L.; Dahi, P. B.; Lin, R. J.; Scordo, M.; Perales, M. A.; Leslie, L. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A comparative analysis of infectious complications in patients with multiple myeloma treated with BCMA-targeted bispecific antibodies and CAR T-cell therapy
    Meeting Abstract

    Nath, K.; Shekarkhand, T.; Costa, B. A.; Nemirovsky, D.; Derkach, A.; Nishimura, N.; Farzana, T.; Rueda, C.; Chung, D.; Landau, H.; more...
    Blood (2023)

    Fulltext@MSK | Save